Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

FSU assistant professor unlocks mysteries of KSHV infection

In the early days of the AIDS epidemic, a once-rare form of cancer known as Kaposi's sarcoma emerged as a frequent harbinger of HIV. Its stigma was best illustrated by Tom Hanks, who portrayed a gay man trying to conceal the cancerous skin lesions from his co-workers in the 1993 movie "Philadelphia."

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

National Cancer Survivors Day to be held on June 5th 2011

The 24th National Cancer Survivors Day will be held on June 5th this year. "This annual event is a national recognition that we have made significant progress in the fight against cancer," said Dr. Patricia Robinson, director of Loyola University Health System's Cancer Survivorship Program. Robinson sees cancer survivors at Loyola's main campus in Maywood and at the Loyola Center for Health at Wheaton.

3 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, Inc. and VisiInc PLC (VZJ) have entered into an agreement to launch MMRGlobal’s patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product. Initially, the two companies will collaborate on offering products and services jointly to the health technology market in Australia, which is currently projected to be as much as $2.4 billion this year.

2 Jun 2011

MMRGlobal, VZJ to launch consumer and professional health IT products

MMRGlobal, Inc. and VisiInc PLC have entered into an agreement to launch MMRGlobal's patented consumer and professional health IT products and services, including MMRPro for healthcare professionals and the MyMedicalRecords Personal Health Record (PHR), on the Visi platform utilizing the Vistime product.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

Leukemia protein plays a role in Alzheimer's disease

After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease.

25 May 2011

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating complete eradication of the cancer in cell and animal studies.

25 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

Study: Full access to personal medical record increases cancer patient's trust in physicians

A new analysis has found that allowing full access to personal medical records increases satisfaction without increasing anxiety in newly diagnosed cancer patients. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that providing accurate information to patients through medical records can be a beneficial complement to verbal communication with their physicians.

23 May 2011

Lymphoma News and Research

Further Reading

FSU assistant professor unlocks mysteries of KSHV infection

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

National Cancer Survivors Day to be held on June 5th 2011

Delayed treatment could prove effective in certain medical conditions

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, VZJ to launch consumer and professional health IT products

Lymphoma vaccine extends disease-free survival by 14 months

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Leukemia protein plays a role in Alzheimer's disease

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Study: Full access to personal medical record increases cancer patient's trust in physicians

New insights into bone diseases

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News